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Abstract
The treatment of patients with large hemispheric ischaemic stroke
accompanied by massive space-occupying oedema represents
one of the major unsolved problems in neurocritical care medicine.
Despite maximum intensive care, the prognosis of these patients is
poor, with case fatality rates as high as 80%. Therefore, the term
‘malignant brain infarction’ was coined. Because conservative
treatment strategies to limit brain tissue shift almost consistently
fail, these massive infarctions often are regarded as an untreatable
disease. The introduction of decompressive surgery (hemicraniec-
tomy) has completely changed this point of view, suggesting that
mortality rates may be reduced to approximately 20%. However,
critics have always argued that the reduction in mortality may be
outweighed by an accompanying increase in severe disability. Due
to the lack of conclusive evidence of efficacy from randomised
trials, controversy over the benefit of these treatment strategies
remained, leading to large regional differences in the application of
this procedure. Meanwhile, data from randomised trials confirm the
results of former observational studies, demonstrating that hemi-
craniectomy not only significantly reduces mortality but also signifi-
cantly improves clinical outcome without increasing the number of
completely dependent patients. Hypothermia is another promising
treatment option but still needs evidence of efficacy from rando-
mised controlled trials before it may be recommended for clinical
routine use. This review gives the reader an integrated view of the
current status of treatment options in massive hemispheric brain
infarction, based on the available data of clinical trials, including the
most recent data from randomised trials published in 2007.
Introduction
Subtotal or complete middle cerebral artery (MCA) territory
infarctions, including the basal ganglia, occasionally with
additional infarction of the anterior cerebral artery (ACA) or
the posterior cerebral artery (PCA) or both, are found in 1%
to 10% of patients with supratentorial infarcts [1-3]. They are
commonly associated with serious brain swelling, which
usually manifests itself between the second and the fifth day
after stroke onset [1-8]. Space-occupying cerebral infarction
is a life-threatening event. Mass effect leads to the destruc-
tion of formerly healthy brain tissue and, in severe cases, to
extensive brain tissue shifts resulting in transtentorial or uncal
herniation and brain death [3,6,9]. These complications are
responsible for the rapid neurologic deterioration seen in
such patients [1]. In intensive care-based prospective series,
the case fatality rate of these patients was approximately
78% despite maximum medical therapy [3,10,11]. For these
catastrophic cerebral infarcts, the term ‘malignant infarction’
was coined by Hacke and colleagues [3] in 1996.
Clinically, these patients present with dense hemiplegia, head
and eye deviation, and multimodal hemineglect; global
aphasia coexists when the dominant hemisphere is involved
[2,3]. The National Institutes of Health Stroke Scale score is
typically greater than 20 when the dominant hemisphere is
involved and greater than 15 when the nondominant hemi-
sphere is involved [12,13]. They show a rapidly progressive
deterioration of consciousness over the first 24 to 48 hours
and frequently a reduced ventilatory drive [3]. Neuroimaging
typically shows definite infarction of at least two thirds of the
MCA territory, including the basal ganglia, with or without
additional infarction of the ipsilateral ACA or the PCA
territories, or an infarct volume of greater than 145 cm3 using
diffusion-weighted imaging [14-18]. Because of an increas-
ing number of young patients suffering from brain infarction (a
group of patients at particular danger of malignant infarction),
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finding an optimal treatment solution has made this a most
urgent topic in neurointensive care medicine during the last
decade.
Treatment options
1. Conservative treatment
1.1. General stroke treatment
As far as blood pressure, blood glucose level, body core
temperature control, fluid and nutrition management, and
prophylaxis of deep venous thrombosis are concerned,
patients with malignant MCA infarctions are treated
according to the current guidelines of general ischaemic
stroke treatment [19-21]. There are some modifications:
Induced hypertension may be useful in case of haemo-
dynamic relevant vessel stenoses or to maintain critical
perfusion in the presence of radiologically confirmed penumbra
[22]. However, there are no controlled trials to confirm this,
and available data are contradictory [23,24]. In a prospective
trial in patients with malignant MCA infarction, induced
hypertension increased cerebral perfusion pressure (CPP)
without a relevant increase of intracranial pressure (ICP) [25].
An exception is made in patients receiving decompressive
surgery. In these cases, systolic blood pressure during the
postoperative phase of the first 8 hours after surgery is kept
at 140 to 160 mm Hg to avoid severe bleeding [26].
Previous recommendations of elevation of the head of 30° in
patients with malignant MCA infarction should not generally
be followed. The idea is that head elevation may improve
venous drainage. Furthermore, an upright body positioning
reduces the risk of nosocomial infections [27-29]. In fact,
although elevation of the head may decrease ICP, the effect
on CPP is less predictable. In several studies, head elevation
increased CPP [30-32], decreased CPP [33,34], or left CPP
unaltered [35-37]. Most of these studies investigated patients
with traumatic brain injury or subarachnoid haemorrhage.
However, in large ischaemic stroke, different pathophysio-
logical aspects such as the possibility of salvaging tissue in
the ischaemic penumbra must be taken into consideration.
Only one study has investigated the effect of body
positioning in patients with large hemispheric ischaemic
stroke [34]. According to the results, a plane positioning of
the head is recommended. Only in case of considerable
increases in ICP or in patients at high risk of nosocomial
infections, a moderate elevation of the head of 15° to 30° is
recommended, always depending on the CPP [34]. Any form
of compression of the jugular veins should be avoided.
As soon as ventilatory drive is depressed, airway protection
becomes paramount, necessitating intubation, ventilation, and
sedation. Patients should be intubated at a Glasgow Coma
Scale (GCS) score of lower than 8, or if there are any signs
of respiratory insufficiency (partial pressure of oxygen [pO2]
of less than 60 mm Hg or partial pressure of carbon dioxide
[pCO2] of greater than 48 mm Hg) or signs of ineffective
swallowing or cough reflexes, or if the airway is compromised
[38]. Deep sedation is recommended to avoid uncontrolled
increases of ICP [27,28]. The following parameters should be
targeted: PaO2 (arterial partial pressure of oxygen) above 75
mm Hg and arterial partial pressure of carbon dioxide
(PaCO2) of 36 to 44 mm Hg. In case of raised ICP, the
ventilation mode should be changed: Minute ventilation
should be adjusted to maintain PaCO2 levels between 35
and 40 mm Hg and pO2 above 100 mm Hg. A minimum of
5 cm H2O of positive end-expiratory pressure and a minimum
FiO2 (fraction of inspired oxygen) to maintain SaO2
(saturation of oxygen [arterial blood]) above 90% are
advocated [26,27,39,40].
All patients with malignant MCA infarction should be treated
at an experienced neurointensive care unit [26-28]. The
treatment options listed below can be effective only with
detailed haemodynamic, neuroimaging, and invasive multi-
modal monitoring tools (at least ICP and CPP, measurement
in the ipsilateral side), the possibility of rapid interventions,
and an experienced neurosurgical department in house. CPP
measurement and repeated neuroimaging are strongly
recommended. ICP alone is not a good parameter for
neurologic deterioration and does not monitor brain
displacement [6].
1.2. Anti-oedema therapy
The use of osmotic agents is based on the idea of creating an
osmotic pressure gradient over the semipermeable membrane
of the blood-brain barrier and thereby drawing interstitial and
intracellular water from the swollen brain into intravascular
spaces. For the treatment of brain oedema after stroke,
mannitol, glycerol, hydroxyethyl starch, and hypertonic saline
are currently the most widely used [41]. According to the
current guidelines, osmotherapy should be started in the case
of increases of ICP [19-21]. The use of mannitol (100 ml of
20% solution or 0.5 to 1.0 g/kg every 4 to 6 hours; maximum
daily dose, 2.5 g/kg), glycerol (250 ml of 10% solution, four
times per day), or hydroxyethyl starch (6% hetastarch in 0.9%
NaCl injection, 100 to 250 ml every 8 hours; maximum daily
dose, 750 ml) is recommended. Onset of action of these
substances is within minutes, and the duration is as long as 4
to 8 hours [27,28,41,42]. In repeated use, dosage depends
on serum osmolality, which should be targeted at 315 to
320 mOsmol. Hyperosmolar saline solutions (10% NaCl,
75 ml, repeated doses) may be used as an alternative. The
advantage of hyperosmolar saline is that it is actively excluded
from an intact blood-brain barrier [43]. Another advantage is
that it can be combined with mannitol because it counteracts
mannitol-induced hyponatremia, which develops in almost
every patient treated by repeated doses of mannitol [44,45].
Steroids are widely used to reduce oedema in brain tumours.
However, they have not shown any benefit for brain oedema
treatment in ischaemic stroke, although there are no trials
investigating the use of steroids in space-occupying ischaemicPage 3 of 14
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stroke [46-49]. In addition, the rate of infections and
complications in patients with diabetes mellitus is significantly
increased with steroids.
1.3. Intracranial pressure-lowering therapies
Barbiturates have been administered in a variety of clinical
conditions to control elevated ICP, especially in head trauma.
Barbiturates may be helpful in acute ICP crisis in those
patients awaiting more definitive treatment. Their routine use,
however, is discouraged [27,28,50].
Buffer solutions may be used as an option when other
interventions have failed. Tris-hydroxy-methyl-aminomethane
(THAM) (Tris buffer) is given by continuous intravenous
infusion via a central venous catheter (1 mmol/kg as bolus
infusion over 45 minutes followed by 0.25 mmol/kg-hour,
aiming for a target arterial pH of 7.5 to 7.55) [28]. THAM can
be used to raise blood pH independently from respiratory
function. The mode of action is probably related to
neutralization of an acidosis-related vasodilatation and thus a
decrease of ICP [28,51]. ICP should fall by 10 to 15 mm Hg
within 15 minutes after bolus infusion; otherwise, treatment is
not effective [27,28].
Hyperventilation is not recommended unless intracranial
hypertension cannot be controlled by any other therapy and
the patient is considered a candidate for more definitive
treatment such as decompressive surgery [27,28]. The
patient’s respiratory mode is adjusted for PaCO2 (target 30
to 35 mm Hg) and venous oxygenation with jugular bulb
oxymetry (>50%), which is best achieved by raising the
ventilation rate at a constant tidal volume. After pCO2 target
is reached, it may take up to 30 minutes until ICP is reduced
by 25% to 30%. Prolonged hyperventilation is discouraged
because the effect wears off within 3 to 4 hours [27,28].
So far, none of these therapeutic strategies is supported by
adequate evidence of efficacy from experimental studies or
randomised clinical trials. To understand why medical treat-
ment alone often fails to prevent clinical deterioration, the
following points have to be remembered: (a) Clinical
deterioration usually is not due to increases of global ICP but
to massive local swelling and tissue shifts. Increase of ICP is
a secondary late-stage result and represents a terminal and,
most likely, an irreversible event that occurs when mass
expansion exceeds intracranial compliance. (b) Many agents
can work only at an intact blood-brain barrier, which is usually
severely compromised in massive cerebral ischaemia. (c)
CPP and midline shift are the major surrogate markers of
treatment in massive infarction. ICP values are not associated
with the extent of midline shift nor do they predict fatal
outcomes, and reduction of ICP is not necessarily associated
with an increase in CPP [52].
Therefore, from a pathophysiological point of view, all of the
above-mentioned therapeutic strategies may be effective only
for a short period of time, if at all, but are doomed to fail in the
long term [44,53]. Several reports suggest that they are not
only ineffective but even detrimental [3,9,34,41,44,45,50,
54-61]:
Osmotic therapy with hyperosmolar agents aimed at lowering
ICP and reducing brain oedema by drawing water from
infarcted tissue may be detrimental by primarily dehydrating
intact brain, contracting healthy brain tissue volume, thereby
aggravating pressure differentials, and causing devastating
shifts of brain tissue [6,42,44,58,62].
In malignant infarctions, there are large areas where the
blood-brain barrier is significantly disrupted. Hyperosmolar
agents have been demonstrated to accumulate in infarcted
brain tissue, aggravating brain oedema and space occupation
instead of reducing them and thereby (especially in the case
of repeated use) worsening brain tissue shifts [55,59]. In
addition, after discontinuing hyperosmolar therapy, rebound
effects may occur [60,63-65].
Prolonged hyperventilation-induced hypocarbia and consider-
able decreases in cerebral blood flow by cerebral vaso-
constriction both aggravate ischaemic brain injury [54,66-68].
Profound hyperventilation may also jeopardise oxygen
delivery to the brain tissue at risk. The underlying physio-
logical mechanism is the Bohr effect: In the presence of
carbon dioxide, the dissociation of oxygen from haemoglobin
increases. A decrease in blood carbon dioxide by hyper-
ventilation increases the affinity of oxygen to haemoglobin.
This leads to a reduction in brain tissue pO2 and, as a result,
to increased ischaemic damage indicated by increases in
extracellular glutamate, pyruvate, and lactate [69,70].
In some patients with poor cerebral compliance, strict
hyperventilation may cause paradoxical ICP elevation by
increasing thoracic venous and cerebrospinal fluid pressure.
Other side effects include barotrauma and hypokalemia. As
with osmotherapy, adverse rebound effects may occur if
normoventilation is resumed too rapidly [26,28,54].
Barbiturates often do not lead to sustained control of ICP but
may reduce CPP [50,71-75]. In addition, treatment may
cause severe side effects such as hypotension, decreased
cardiac performance, or severe infections. Cardiovascular
side effects may be aggravated by concomitant dehydration
advocated by osmotherapy and reduced cardiac filling
pressures [28,50].
As a result, none of the conservative treatment options has
shown a beneficial effect on outcome in clinical trials, except
for glycerol, for which a few clinical trials demonstrate an
effect on short-time survival. However, glycerol also failed to
demonstrate a long-term benefit [46,61,76]. This failure of
conservative treatment is reflected by our clinical experience:
In larger case series of maximum conservative treatment in
Available online http://ccforum.com/content/11/5/231malignant MCA infarction, case fatality rates are 53% to 78%
[3,11,77,78].
2. Mild to moderate hypothermia
Induced hypothermia is defined as physical or pharmaco-
logical lowering of the physiological body core temperature to
36.0°C to 36.5°C (minimal hypothermia), 33.0°C to 35.9°C
(mild hypothermia), 28.0°C to 32.9°C (moderate hypo-
thermia), or 10.0°C to 27.9°C (deep hypothermia) [79]. It is
well known in ischaemic stroke that body temperature on
admission and during the first 24 hours is associated with the
extent of ischaemic damage and is an independent predictor
of mortality and outcome [80-82].
Although the neuroprotective effect of hypothermia has been
known since the 1950s, the earliest experimental findings in
ischaemic stroke were reported in the late 1980s [83,84].
There are numerous animal experiments demonstrating
promising results, but only a few of them on massive cerebral
infarctions [85-88]. The beneficial effect was pronounced
when hypothermia was started early and continued for more
than 24 hours [89-91].
Only one randomised trial has investigated mild-moderate
hypothermia in severe, but not necessarily malignant, stroke
(cooling for acute ischaemic brain damage, or COOL-AID).
Patients were randomly assigned to either hypothermia or
standard medical treatment. Target temperature in the pilot
trial was 32°C maintained for 12 to 72 hours. In the subse-
quent phase I trial, a target temperature of 33°C was
maintained for 24 hours. Due to the small sample sizes, the
studies did not show statistically significant differences in
mortality or functional outcome [92,93]. There are no
published controlled, randomised, or prospective compara-
tive clinical studies of hypothermia in malignant MCA
infarction. Available clinical studies in malignant cerebral
infarction are listed in Table 1.
These report mortality rates of between 17% and 48%
(Table 2). Data on functional outcome are summarized in
Table 3. Only one study has evaluated functional outcome
after 6 months in patients with malignant MCA infarction
treated by hypothermia, and only 10 patients were involved
[94]. Data on long-term outcome are completely lacking
(Table 3).
Hypothermia in these studies was associated with a high rate
of complications, the most frequent being pneumonia, severe
bradycardia and heart failure with severe hypotension, and
severe thrombocytopenia and coagulopathy. Especially in the
rewarming phase, a high percentage of patients developed
severe increases in ICP. Increased ICP and herniation were
the most common reasons for early mortality [95]. Most
studies on hypothermia in ischaemic stroke used body
Critical Care    Vol 11 No 5 Jüttler et al.
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Table 1
Studies on hypothermia in malignant hemispheric infarction
Target  Time to induction of  Duration of 
Authors Number temperature hypothermia (hours) hypothermia (hours)
Schwab et al., 1998 [95] 25 33°C (external cooling) 4-24, mean 14 ± 7 48-72
Schwab et al., 2001 [134] 50 32°C-33°C (external cooling) 4-75, mean 22 ± 9 24-72
Georgiadis et al., 2001 [99] 6 33°C (endovascular cooling) 12-58, mean 28 ± 17 48-78
Georgiadis et al., 2002 [124] 19 33°C (n = 8 endovascular cooling;  18-24, mean 24 24-116
n = 11 external cooling)
Milhaud et al., 2005 [94] 12 32°C-33°C (external cooling) 4-24, mean 11 ± 7 120-504
Table 2
Mortality data on patients with malignant middle cerebral artery infarction treated with hypothermia
Mean age  Mortality in  Mortality up  Mortality up  Mortality up 
Authors Number (years) hospital to 3 months to 6 months to 12 months
Schwab et al., 1998 [95] 25 49 44% 48% NA NA
Schwab et al., 2001 [134] 50 57 38% 38% NA NA
Georgiadis et al., 2001 [99]a 6 65 17% NA NA NA
Milhaud et al., 2005 [94]b 10 52 50% 50% 50% NA
aTarget temperature in one patient 34.5°C. bTwo patients were excluded in this analysis because they received hemicraniectomy in addition to
hypothermia due to worsening of cerebral oedema on day 1 and day 7, respectively; both survived. NA, not available.temperature for monitoring. It has to be kept in mind,
however, that brain temperature is 0.5°C ± 0.3°C above
rectal temperature, that temperature within the brain may vary
up to 1°C, and that initial temperature in the ischaemic
hemisphere is 0.8°C higher than in the healthy hemisphere
[84,96-98].
As long as there is no sufficient evidence of benefit,
hypothermia should be used only in the setting of clinical
trials. Hypothermia is an invasive procedure that needs treat-
ment in an experienced ICU, including ventilation, relaxation,
and measurement of ICP. External cooling is complicated,
especially in adipose patients because of the comparatively
long time for cooling with increased use of muscle relaxants
and anaesthetics. If available, endovascular cooling should be
used because the target temperature can be obtained
comparatively quickly (approximately 3.5 hours) [92,93,99].
Instead of passive rewarming, controlled rewarming and long
rewarming periods (+0.1°C to 0.2°C per 2 to 4 hours) should
be used to avoid increases in ICP or decreases in CPP
[100]. Cooling of the head alone seems to be insufficient
[96], although further clinical evaluation is required and
devices are still being developed [101,102].
3. Decompressive surgery
Decompressive surgery in large ischaemic strokes dates
back to as early as 1935 [103]. It is the only available
treatment that primarily addresses mass effect, based on
simple mechanical reasoning. The rationale is to remove a
part of the neurocranium in order to create space to accom-
modate the swollen brain, to avoid ventricular compression,
to reverse brain tissue shifts, and to prevent secondary
mechanical tissue damage. Normalisation of ICP and tissue
oxygenation is more a secondary effect [9,104-108].
Two different techniques are used: external decompression
(removal of the cranial vault and duraplasty) or internal
decompression (removal of nonviable, infarcted tissue [that
is, in the case of malignant MCA infarction, temporal lobec-
tomy]). The two can be combined [109,110]. In theory,
resection of the temporal lobe may reduce the risk of uncal
herniation. However, this has never been proven consistently
by clinical studies, which show similar results as series using
external decompression [111,112]. Resection of infarcted
tissue is more complicated, and it is difficult to distinguish
between already infarcted and potentially salvageable tissue.
Therefore, in most institutions, external decompressive
surgery (consisting of a large hemicraniectomy and dura-
plasty) is performed: In short, a large (reversed) question
mark-shaped skin incision based at the ear is made. A bone
flap with a diameter of at least 12 cm (including the frontal,
parietal, temporal, and parts of the occipital squama) is
removed. Additional temporal bone is removed so that the
floor of the middle cerebral fossa can be explored. Then the
dura is opened and an augmented dural patch, consisting of
homologous periost and/or temporal fascia, is inserted
Available online http://ccforum.com/content/11/5/231
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.(usually, a patch of 15 to 20 cm in length and 2.5 to 3.5 cm in
width is used). The dura is fixed at the margin of the
craniotomy to prevent epidural bleeding. The temporal
muscle and the skin flap are then reapproximated and
secured. In surviving patients, cranioplasty usually is
performed after 6 to 12 weeks, using the stored bone flap or
an artificial bone flap (Figures 1 and 2). Complications occur
rarely and include postoperative epidural and subdural
haemorrhage and hygromas or wound and bone flap
infections [77,109]. These can be recognized easily and
usually do not contribute to perioperative mortality. A more
common and far more serious problem is a hemicraniectomy
that is too small. Because the proportion of brain tissue to be
allowed to shift outside the skull is closely related to the
diameter of the bone flap (which is removed), small
hemicraniectomies not only are insufficient but may lead to
herniation through the craniectomy defect [113].
Ventriculostomy is not recommended; although it may help to
decrease ICP by allowing drainage of cerebrospinal fluid, it
promotes brain tissue shifts at the same time and therefore
may be detrimental.
Between 1935 and 2007, more than 80 case reports and
series of patients with malignant brain infarctions including
more than 1,700 patients have been published. Larger case
series were not published until 1995 [77]. Only a few
prospective trials have compared decompressive surgery
with conservative treatment. Some of them used historical
control groups, and most control groups consisted of
patients with a higher age, more comorbidity, and (more
frequently) lesions of the dominant hemisphere
[3,77,104,109,111,114-122]. These studies report mortality
rates of 0% to 33% in surgically treated patients compared
with 60% to 100% in conservatively treated patients. In a
review by Gupta and colleagues [123] analysing all available
individual patient data from 138 patients, the overall mortality
rate after hemicraniectomy after a period of 7 to 21 months
was 24%. Only one study compared decompressive surgery
with hypothermia [124], and one study compared mild
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Figure 1
Hemicraniectomy: external decompressive surgery technique. I. Fronto-
temporo-parietal hemicraniectomy: (a) schematic drawing of the
hemicraniectomy defect, (b) incision, (c) craniectomy borders (to the
skull base), (d) tense dura mater with swollen brain underneath. II. Dura
mater is removed for duraplasty: (a) preparation, (b) dura stretched on
aluminium foil. III. Dura incisions: (a) schematic drawing of incisions, 
(b) preparation. IV. Insertion of the dura (duraplasty). V. Bone flap is
stored at –80°C. Cranioplasty is performed after 6 to 12 weeks.
Figure 2
Left hemispheric malignant middle cerebral artery infarction after
hemicraniectomy (magnetic resonance imaging). The swollen brain is
allowed to expand outside.hypothermia plus hemicraniectomy with hemicraniectomy
alone [125] (Tables 4 and 5).
Various trials suggest that decompressive surgery not only
reduces mortality but also increases the number of patients
Available online http://ccforum.com/content/11/5/231
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Table 4
Mortality data in patients with malignant middle cerebral artery infarction: studies with comparative data on conservative
treatment versus decompressive surgery
Patients Patients 
treated with  treated with  Mean  Mortality  Mortality  Mortality  Mortality 
conservative  decompressive  age  in  up to  up to  up to 
Authors treatment surgery (years) hospital 3 months 6 months 12 months
Delashaw et al., 1990 [118]a 4 9 NA vs. 57 100% vs. 0% 100% vs. 11% 100% vs. NA 100% vs. NA
Steiger 1991 [119]b 7 8 NA 100% vs. 25% 100% vs. 25% 100% vs. 25% NA
Rieke et al., 1995 [77],  55 63 56 vs. 50 78% vs. 25% NA vs. 25% NA NA
Hacke et al., 1996 [3], 
Wirtz et al., 1997 [104], 
Schwab et al., 1998 [109]c
Holtkamp et al., 2001 [114]d 12 12 73 vs. 65 83% vs. 17% 83% vs. 25% 83% vs. 25% 83% vs. 33%
Mori et al., 2001 [120]  15 19 72 vs. 63 60% vs. 11% 67% vs. 16% NA NA
Mori et al., 2004 [111]e 15 19 72 vs. 65 62% vs. 12% NA 71% vs. 24% NA
Kuroki et al., 2001 [121]f 7 8 80 vs. 72 86% vs. 13% NA NA NA
Cho et al., 2003 [115]g 10 42 64 vs. 63 80% vs. 29% NA NA NA
Maramattom et al., 2004 [116]h 10 14 63 vs. 55 60% vs. 0% NA NA NA
Yang et al., 2005 [122]i 14 10 66 vs. 59 64% vs. 10% 64% vs. 10% NA NA
Wang et al., 2006 [117]j 41 21 67 vs. 62 NA NA 22% vs. 29% NA
Patients 
Patients  treated  with Mean  Mortality Mortality Mortality Mortality 
treated with  decompressive  age  in  up to  up to  up to 
Authors hypothermia surgery (years) hospital 3 months 6 months 12 months
Georgiadis et al., 2002 [124] 19 17 56 vs. 52 47% vs. 12% NA NA NA
Patients 
treated with  Patients 
decompressive treated  with Mean  Mortality Mortality Mortality Mortality 
surgery + decompressive  age  in  up to  up to  up to 
Authors hypothermia surgery (years) hospital 3 months 6 months 12 months
Els et al., 2006 [125]k 12 13 49 vs. 49 8% vs. 15% 8% vs. 15% 8% vs. 15% NA
aNot randomised. All four patients in the nonintervention group had a dominant MCA infarction, and all nine patients in the intervention group had a
nondominant MCA infarction.
bNot randomised. All patients were younger than 60 years. There is a selection bias because conservatively treated patients were not regarded as
being suitable for surgery.
cNot randomised. These studies represent the largest case series in the literature using the case series of Hacke and colleagues (1996) [3] as
historical control group. Mortality rates of early versus delayed surgery were 16% versus 34%.
dNot randomised. There is a selection bias by advanced age and more comorbidity in conservatively treated patients. All patients were older than
55 and younger than 75 years.
eNot randomised. There is a selection bias because treatment decision was based primarily on the consent by the patient´s relatives. Some
patients received internal decompression.
Mortality rates of early versus late surgery were 19% versus 28%. The case series of 2004 included the patients of the case series of 2001.
fNot randomised. The study used historical controls.
gNot randomised. Mortality rates of ultra-early (<6 hours) versus delayed surgery were 8% versus 37%.
hNot randomised. Hemicraniectomy was performed only in patients, who deteriorated clinically.
iNot randomised.
jNot randomised. There was no difference between late and early hemicraniectomies.
kRandomised. Twelve patients received mild hypothermia (35°C) in addition to hemicraniectomy. In the group treated by hemicraniectomy alone
more patients had a right-sided infarction and additional infarction of the ACA or PCA.
ACA, anterior cerebral artery; NA, not available; PCA, posterior cerebral artery.with independent functional outcome without increasing the
number of severely disabled patients [109,111,115,118,
126]. Other studies doubt these results, especially in patients
with increased age and with additional infarction of the ACA
or PCA [116,117,122,127,128]. Among other predictors
that have been proposed to predict unfavourable outcome
are preoperative midline shift, low preoperative GCS,
presence of anisocoria, early clinical deterioration, and
internal carotid artery occlusion [129,130]. In the review by
Gupta and colleagues [123], age was the only prognostic
factor for poor outcome, whereas time to surgery, the
presence of brainstem signs prior to surgery, and additional
infarction of the ACA or PCA territory were not associated
with outcome. Data from comparative studies and reviews are
summarized in Tables 6 and 7.
These controversial results lead to constant discussion
among experts about the benefit of decompressive surgery in
malignant MCA infarction and to large regional differences in
the application of the procedure. This dilemma could be
resolved only by randomised trials. Since 2000, five
randomised trials have been conducted: the American
HeADDFIRST (Hemicraniecomy And Durotomy Upon
Deterioration From Infarction Related Swelling Trial), the
French DECIMAL (DEcompressive Craniectomy In
MALignant middle cerebral artery infarcts) trial, the Dutch
HAMLET (Hemicraniectomy After Middle cerebral artery
infarction with Life-threatening Edema Trial), the Philippine
HeMMI (Hemicraniectomy For Malignant Middle Cerebral
Artery Infarcts) trial, and the German DESTINY (DEcom-
pressive Surgery for the Treatment of malignant INfarction of
the middle cerebral arterY) trial [16-18,131,132].
DESTINY and DECIMAL were stopped early in 2006, and the
results were published recently [16,17]. In both trials,
decompressive surgery significantly reduced mortality, but
the primary endpoint in both trials, dichotomization of the
modified Rankin scale (mRS) score of less than or equal to 3,
failed to show statistically significant results. Nevertheless,
both trials were stopped not only because of ethical
considerations to continue randomisation, but also because
of expectations of a prospectively planned pooled analysis of
the three European trials (DECIMAL, DESTINY, and
HAMLET). This pooled analysis is the first in the field of
stroke in which individual patient data from three different
randomised trials were pooled while these trials were still
ongoing. Of the 93 patients who were included, 51 were
randomly assigned to decompressive surgery and 42 to
conservative treatment. Results demonstrate that
decompressive surgery (a) significantly reduces mortality
(71% versus 22%, p <0.0001, absolute risk reduction [ARR]
50%), (b) significantly increases the chance to survive with
an mRS score of less than or equal to 4 (that is, not being
bedridden and completely dependent) (24% versus 75%,
p <0.0001, ARR 51%), and (c) also significantly increases
the chance to survive with an mRS score of less than or equal
to 3 (that is, being able to walk and being independent in at
least some activities of daily living) (21% versus 43%,
p <0.014, ARR 23%) (Figures 3 and 4) [133]. There is no
statistically significant heterogeneity between the three trials,
and the treatment effects remain essentially the same for all
analyses if baseline differences between the treatment
groups are taken into account. The resulting numbers needed
to treat are 2 for survival, 2 for the prevention of an mRS
score of 5 or death, and 4 for the prevention of an mRS score
of 4 or 5 or death. Decompressive surgery was beneficial in
all predefined subgroups, including age (dichotomized at
50 years), presence of aphasia, and time to randomisation
(dichotomized at 21.5 hours), as measured by an mRS score
of less than or equal to 4 at 12 months.
Summary
For many years, there has been no agreement among experts
concerning the question of which treatment is beneficial in
patients with malignant MCA infarctions. In comparison with
the usually unsuccessful conservative treatment strategies,
hypothermia and decompressive surgery seem to be much
more promising therapies [9,53,95]. Although hypothermia
has been demonstrated to be feasible in patients with large
hemispheric infarctions, data on safety and efficacy are
currently insufficient to recommend hypothermia in patients
with malignant infarctions outside clinical trials [99,134].
Because of promising results from numerous case reports,
retrospective case series, and a small number of prospective
studies, decompressive surgery has already been increasingly
Critical Care    Vol 11 No 5 Jüttler et al.
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Table 5
Mortality data in patients with malignant middle cerebral artery infarction: studies with reviews on conservative treatment versus
decompressive surgery
Patients treated with  Patients treated with 
Authors conservative treatment decompressive surgery Mean age (years) Mortality
Gupta et al., 2004 [123] - 138 50 Overall mortality 24% 
(follow-up 7-21 months)
Morley et al., 2002 [137] Gives an overview on available data.
No trial fulfills the criteria of a randomised controlled study design to be included in a meta-analysis.Available online http://ccforum.com/content/11/5/231
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.incorporated into routine intensive care protocols [77,109,
123]. In 2007, the results from nonrandomised studies were
confirmed by a pooled analysis of three randomised
controlled trials, supporting the widespread opinion among
experts that hemicraniectomy in malignant MCA infarction not
only reduces mortality but also leads to an improved outcome
of the survivors without increasing the number of completely
dependent patients [133]. So far, early hemicraniectomy is
the only effective treatment in malignant ischaemic stroke.
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Figure 3
Mortality and functional outcome after conservative treatment in
patients with malignant middle cerebral artery infarction. Results from
randomised controlled trials. The pooled analysis includes 93 patients
(all patients from DECIMAL and DESTINY and 23 patients from
HAMLET). DECIMAL, DEcompressive Craniectomy In MALignant
middle cerebral artery infarcts; DESTINY, DEcompressive Surgery for
the Treatment of malignant INfarction of the middle cerebral arterY;
HAMLET, Hemicraniectomy After Middle cerebral artery infarction with
Life-threatening Edema Trial; mRS, modified Rankin scale.
Figure 4
Mortality and functional outcome after hemicraniectomy in patients with
malignant middle cerebral artery infarction. Results from randomised
controlled trials. The pooled analysis includes 93 patients (all patients
from DECIMAL and DESTINY and 23 patients from HAMLET).
DECIMAL, DEcompressive Craniectomy In MALignant middle cerebral
artery infarcts; DESTINY, DEcompressive Surgery for the Treatment of
malignant INfarction of the middle cerebral arterY; HAMLET,
Hemicraniectomy After Middle cerebral artery infarction with Life-
threatening Edema Trial; mRS, modified Rankin scale.Competing interests
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